Purpose & People

Pharmabiotic Research Institute (PRI) | EU Microbiome Regulatory Science Center

The Pharmabiotic Research Institute (PRI) is Europe’s first Microbiome Regulatory Science expertise center – our purpose is to support and foster the development of innovations emerging from microbiome science, by bridging stakeholders in industry, academia, and EU regulatory representatives.

Our mission is to educate and contribute to the conditions of success for future innovations emerging from microbiome science by supporting and communicating on regulatory science developments within and outside of our ecosystem.

Our ultimate objective: see these innovations achieve EU marketing authorization, for the ultimate benefit of citizens and patients.

To realize this vision, we apply a collaborative method called the Share & Learn Approach – a pre-competitive process which combines microbiome expertise with strong regulatory science principles. These efforts are fundamental to identifying and confirming the specific requirements for the development of microbiome-based innovations.

Founded in 2010 by microbiologists from industry and academia, we operate as an independent, non-profit organization, employing only full-time paid staff, and adhering to a transparent governance structure, required by French law according to our corporate status (association loi 1901). This ensures that we avoid any overt conflict of interest when interacting with national and European regulatory authorities.

Governance

All PRI Members nominate an Official Member Representative – this individual represents the Member Organization during the annual General Assembly, and may represent their organization on the Board of Directors.

Each PRI Member, regardless of member type, has one vote in elections (General Assembly, Board members).

Executive Committee
(2024 – 2026)

Eleni Tsompanidou
President
Head of Microbial Discovery and Development
Winclove Probiotics

   

Gianfranco Grompone
1st Vice President
Chief Scientific Officer
BioGaia AB

   

Sylvie Binda
2nd Vice President
Vice President R&D
Lallemand Health Solutions
   

Sandrine Claus
Secretary
Founder & CEO​
Starfish bioscience

.   

Stanislas Desjonquères
Treasurer
CEO
Nexbiome Therapeutics

   

Board of Directors
(2024 – 2026)

Gerardo Rivas Parafita
Manager|Regulatory Affairs EMEA
ADM

   

Nail Nasir
Scientific Manager
Astel Medica

   

Romain Dailliere
Microbiome Program Head
Bioaster

   

Gianfranco Grompone
Chief Scientific Officer
BioGaia AB

   

Adam Jarlfors
Global Regulatory Lead
Ferring Pharmaceuticals

   

Etienne Formstecher
Co-Founder & CEO
GMT Science

   

Charlotte Storni
Global Regulatory Strategy Leader
IFF

   

Patrick Veiga
Research Director
INRAE (MetaGenoPolis)

   

Sylvie Binda
Vice President R&D
Lallemand Health Solutions
   

Katja Conrath
Chief Scientific Officer
MRM Health NV

   

Adam Wilkinson
VP Pre-Clinical Development
Microbiotica

   

Stanislas Desjonquères
CEO
Nexbiome Therapeutics

   

Marco Pane
R&D Director
Probiotical Research

   

Massimo Marzorati
CEO
ProDigest BV

   

Sandrine Claus
Founder & CEO
Starfish bioscience

.   

Ilke De Boeck
Postdoctoral Researcher
University of Antwerp

   

Ana Palmeira de Oliveira
Invited Professor
University of Beira Interior

   

Siobhain O’Mahony
Senior Lecturer
University College Cork

   

Eleni Tsompanidou
Head of Microbial Discovery and Development
Winclove Probiotics

   

Staff

Céline Druart
Executive Director

   

Julie Rodriguez
OMICS Project Manager